MODERN TREATMENT STRATEGY FOR OVERACTIVE BLADDER SYNDROME: FROM STEP THERAPY TO A PERSONALIZED APPROACH
Keywords:
Overactive bladder, urology, urgency, urge urinary incontinence, pharmacotherapy, β3-agonists, anticholinergic drugs, botulinum toxin, neuromodulation, tibial stimulation, personalized treatment.Abstract
Overactive bladder syndrome (OAB) is one of the most common functional lower urinary tract disorders and is characterized by a significant impact on quality of life, sleep, social activity, and work capacity. In recent years, the concept of OAB treatment has undergone significant changes. The traditional stepwise model, based on a sequential transition from behavioral therapy to pharmacotherapy and then to invasive methods, is gradually being transformed into an individualized strategy that takes into account the clinical phenotype, age, comorbidities, cognitive risks, treatment adherence, and patient preferences.
References
1.Cameron AP, Chung DE, Dielubanza EJ et al. The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder. Journal of Urology . 2024;212(1):11–20. https://pubmed.ncbi.nlm.nih.gov/38651651/
2.Harding C., et al. What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel. European Urology . 2023;84(3):302–312. DOI: 10.1016/j.eururo.2023.05.014. https://pubmed.ncbi.nlm.nih.gov/37331921/ Neuromodulation. European Urology Focus . 2023;9(5):765–772. DOI: 10.1016/j.euf.2023.03.008. https://pubmed.ncbi.nlm.nih.gov/37019729/
7.Risks of Dementia After Treatment with an Anticholinergic, Beta-3 Agonist, or Combination of Both for an Overactive Bladder: A Korean National Cohort Study. European Urology Focus . 2024;10(2):306–314. DOI: 10.1016/j.euf.2024.02.002. https://www.sciencedirect.com/science/article/abs/pii/S2405456924000191
8.A Retrospective Database Analysis to Investigate Treatment Patterns and Health Care Resource Utilization in Patients who CYCLe AntiMuscarinics in ENgland (CYCLAMEN). European Urology Focus . 2024;10(4):627–633. DOI: 10.1016/j.euf.2023.09.017. https://headsuphealth.com/request-a-demo/
9.Efficacy and Safety of Eliapixant in Overactive Bladder: The 12-Week, Randomised, Placebo-controlled Phase 2a OVADER Study. European Urology Focus . 2024;10(1):90–97. DOI: 10.1016/j.euf.2023.07.008. https://pubmed.ncbi.nlm.nih.gov/37563004/
10.The Effects of Age, Gender, and Postvoid Residual Volume on Catheterization Rates After Treatment with OnabotulinumtoxinA for Overactive Bladder. European Urology Open Science . 2023;57:98–105. DOI: 10.1016/j.euros.2023.09.013. https://pmc.ncbi.nlm.nih.gov/articles/PMC10658411/
3.Michel MC, Cardozo L., Chermansky CJ et al. Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders. Pharmacological Reviews . 2023;75(4):554–674. DOI: 10.1124/pharmrev.121.000523. https://pubmed.ncbi.nlm.nih.gov/36918261/
4.Funada S., Luo Y., Uozumi R. et al. Multicomponent Intervention for Overactive Bladder in Women: A Randomized Clinical Trial. JAMA Network Open . 2024;7(3). DOI: 10.1001/jamanetworkopen.2024.1784. https://pmc.ncbi.nlm.nih.gov/articles/PMC10938174/
5.Liao L., Li X., Chong T. et al. Efficacy and safety of tibial nerve stimulation using a wearable device for overactive bladder. BJU International . 2024;133(6):760–769. DOI: 10.1111/bju.16330. https://www.sprpainrelief.com/hcp/sprint-pns-system
6.Chartier-Kastler E., Le Normand L., Ruffion A. et al. Five-year Results from the Prospective, Multicenter, Observational SOUNDS Study of Patients with Overactive Bladder Treated with the InterStim System for Sacral
